Comparative Pharmacology
Head-to-head clinical analysis: VEETIDS 250 versus VEETIDS 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VEETIDS 250 versus VEETIDS 500.
VEETIDS '250' vs VEETIDS '500'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VEETIDS '250' is an oral cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP-3, thereby disrupting peptidoglycan cross-linking and leading to cell lysis.
VEETIDS '500' (cefuroxime axetil) is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis. It has activity against both gram-positive and gram-negative bacteria.
250 mg orally every 8 hours for 7-10 days
1 tablet (500 mg) orally twice daily for 7 days.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 24-40 hours in anuria/end-stage renal disease, requiring dose adjustment.
4-6 hours (prolonged in renal impairment; requires dose adjustment if CrCl <30 mL/min)
Primarily renal (≥90% as unchanged drug) via glomerular filtration and tubular secretion; minor biliary/fecal (<5%).
Renal: 60-80% unchanged; biliary/fecal: 15-25% as metabolites
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic